AI-Based Genetic Data Analysis
Clinical genomics platform for hospitals and private labs, providing management, analysis and interpretation of genetic data, and clinical reporting
Secure Genetic Data Storage
Clinical genetic database enabling researchers to securely access and data mine large scale genetic data with associated clinical information
Targeted Drug Discovery
Drug discovery research suite enabling pharma customers to better interrogate large scale clinical genetic data for identification of novel drug targets
Advancing Genetic Diagnosis and Research
Double your diagnostic yields while reducing your turn-around time from hours to minutes with our fully customizable clinical genomic platform which support rare disorders, health screening and others
Double your diagnostic yield
Reduce your turn-around time
Leverage our proprietary technology platform for better Whole Genome Sequencing-based targeted drug discovery, providing interpretation and enrichment of 10x the genome scope
Discover customer successful stories
What Our Clients Say
Lina Abi Mosleh, Ph.D.
Geneyx Analysis is an easy-to-use system for managing our genetic tests. It makes it easy to identify variants of relevance through its integration with various sources of evidence, and its ability to customize reports allows us to present our results to clients in the most useful manner. We strongly recommend it for labs that provide genetic information to clinical care professionals.
Prof. Sergio D.J. Pena, MD, PhD, FRCP(C)
I have had the pleasure of working with VarElect and Geneyx Analysis… which have an uncanny ability in discovering the right “culpable” variant in complex cases studied with whole exome sequence (WES)… both these programs have been extremely useful in our WES analyses. They are simple to use and yet most efficient. Thus, I recommend them very strongly.
NEW YORK – Geneyx Genomex said Monday that it has acquired Toldot Genetics. Geneyx acquired Toldot from biomedical informatics firm BATM Advanced Communications and several minority shareholders, who in return received a 5 percent equity stake in Geneyx. Additional terms of the deal were not disclosed. Geneyx, an Israel-based developer of genomic analysis and interpretation software, will integrate Toldot’s TGex next-generation
NEW YORK –A public-private consortium in Israel will collect samples and sequence genomes from thousands of COVID-19 patients in an effort to identify protective and risk-bearing genetic factors with the hopes of discovering new diagnostic and treatment methods. “This is a rare opportunity to thoroughly and consistently document clinical findings of thousands of patients and sequence their whole genome.”Dr. Hagit